NEOGENOMICS ($NEO) posted quarterly earnings results on Tuesday, October 28th. The company reported earnings of $0.03 per share, beating estimates of $0.02 by $0.01. The company also reported revenue of $187,800,000, beating estimates of $185,607,558 by $2,192,442.
You can see Quiver Quantitative's $NEO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
NEOGENOMICS Insider Trading Activity
NEOGENOMICS insiders have traded $NEO stock on the open market 11 times in the past 6 months. Of those trades, 10 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $NEO stock by insiders over the last 6 months:
- JEFFREY SCOTT SHERMAN (Chief Financial Officer) has made 2 purchases buying 40,000 shares for an estimated $262,426 and 0 sales.
- ANTHONY P. ZOOK (Chief Executive Officer) has made 2 purchases buying 36,800 shares for an estimated $248,872 and 0 sales.
- DAVID BRIAN PEREZ purchased 10,000 shares for an estimated $76,300
- LYNN A. TETRAULT purchased 7,000 shares for an estimated $56,974
- ALICIA C OLIVO (EVP, GC & Business Development) sold 4,918 shares for an estimated $49,180
- WARREN STONE (Pres & Chief Operating Officer) purchased 5,700 shares for an estimated $48,894
- MICHAEL AARON KELLY purchased 5,000 shares for an estimated $38,000
- NEIL GUNN purchased 4,510 shares for an estimated $34,977
- STEPHEN M KANOVSKY purchased 4,000 shares for an estimated $31,124
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
NEOGENOMICS Hedge Fund Activity
We have seen 145 institutional investors add shares of NEOGENOMICS stock to their portfolio, and 111 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BROWN ADVISORY INC removed 3,871,964 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $28,304,056
- JANUS HENDERSON GROUP PLC removed 3,740,466 shares (-65.2%) from their portfolio in Q2 2025, for an estimated $27,342,806
- MILLENNIUM MANAGEMENT LLC removed 3,401,493 shares (-50.6%) from their portfolio in Q2 2025, for an estimated $24,864,913
- GREENHOUSE FUNDS LLLP added 2,722,823 shares (+57.8%) to their portfolio in Q2 2025, for an estimated $19,903,836
- GW&K INVESTMENT MANAGEMENT, LLC added 2,245,210 shares (+977.2%) to their portfolio in Q2 2025, for an estimated $16,412,485
- DEERFIELD MANAGEMENT COMPANY, L.P. added 2,148,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $15,701,880
- LOOMIS SAYLES & CO L P removed 1,752,681 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $12,812,098
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
NEOGENOMICS Government Contracts
We have seen $1,402,482 of award payments to $NEO over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- FISH TESTING BPA FOR VISN1 VA: $500,000
- DIAGNOSTIC REFERENCE LABORATORY TESTING SERVICES: $330,832
- OFF-SITE ANATOMIC PATHOLOGY LAB SERVICES VACCHCS ORDERING PERIOD 5 (6) MONTH TASK ORDER: $325,000
- IMMUNOHISTOCHEMISTRY (IHC) TESTING: $111,500
- IMMUNOHISTOLOGICAL STAINS REFERENCE TESTING: $108,000
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
NEOGENOMICS Congressional Stock Trading
Members of Congress have traded $NEO stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $NEO stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 05/07.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
NEOGENOMICS Analyst Ratings
Wall Street analysts have issued reports on $NEO in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- TD Cowen issued a "Buy" rating on 09/12/2025
- Stephens & Co. issued a "Overweight" rating on 09/02/2025
- Needham issued a "Buy" rating on 08/29/2025
- Piper Sandler issued a "Overweight" rating on 05/06/2025
To track analyst ratings and price targets for NEOGENOMICS, check out Quiver Quantitative's $NEO forecast page.
NEOGENOMICS Price Targets
Multiple analysts have issued price targets for $NEO recently. We have seen 5 analysts offer price targets for $NEO in the last 6 months, with a median target of $11.0.
Here are some recent targets:
- Dan Brennan from TD Cowen set a target price of $12.0 on 09/12/2025
- Mason Carrico from Stephens & Co. set a target price of $11.0 on 09/02/2025
- Mike Matson from Needham set a target price of $14.0 on 08/29/2025
- David Westenberg from Piper Sandler set a target price of $11.0 on 08/04/2025
- Tejas Savant from Morgan Stanley set a target price of $8.0 on 07/30/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
